Introduction
Benzodiazepines are the drugs most frequently prescribed worldwide as tranquilizers, hypnotics, anesthetics, anticonvulsants or muscle relaxants to treat sleeplessness, depression, anxiety and epilepsy. Benzodiazepines are considered to be safer and more effective than barbiturates, but chronic use can produce dependence and abuse (1) . Their intake, in combination with other central nervous system (CNS) depressants such as alcohol, may cause severe respiratory depression, which can lead to death (2) (3) (4) . Benzodiazepine misuse is increasingly associated with suicidal poisoning (5) , driving under the influence of drugs (DUID) (6) and drug-facilitated sexual assault (DFSA) (7 -9) . As such, benzodiazepines are among the most frequently encountered substances in clinical and forensic toxicological analyses, for which the simultaneous analysis of benzodiazepines and their metabolites in biological matrices is of great interest. The most representative difficulties in benzodiazepine analysis derive from the large number of these drugs (more than 50 different benzodiazepines are commercially available for clinical use) and from the possibility that many of them can be metabolized to multiple forms (many metabolites are drug substances in their own right) (10, 11) . For these reasons, screening tests that can provide a rapid qualitative (or semi-quantitative) detection of benzodiazepines with high sensitivity (SENS) and specificity (SPEC) to include both abusive use and low-therapeutic doses are necessary, followed by instrumental techniques based on mass spectrometric detection. Immunoassays (IAs) are widely utilized for their rapidity, flexibility and semi-quantitative results. Urine is one of the preferred matrices for drug analysis, because the concentrations of benzodiazepines and their metabolites are higher in urine than in other biological specimens such as blood, oral fluid and hair.
However, the capability of IAs to detect benzodiazepines is problematic due to the wide variation of the various representatives of this group of drugs in potency, structure, metabolism and elimination. The most critical limitation of IAs is related to the variable immunoreactivity of the antibodies to the diverse structural differences of the benzodiazepine class of drugs, leading to a large incidence of false positives (FPs) and false negatives (FNs) (12) . In forensic laboratories, usually only positive results are investigated by instrumental techniques, while negative (and FN) ones are not. FNs can occur when benzodiazepine compounds with a low immunoreactivity rate are analyzed (i.e., Phase II metabolites, especially glucuronide forms) (13, 14) . It is important to keep in mind these limitations, as in urine specimens benzodiazepine metabolites may be present and there is a risk of quantitative underestimation resulting in a false negativity (15) . Analytical identification by IA is further complicated by the wide ranges of benzodiazepine therapeutic concentrations and metabolic pathways. Thus, these types of assays are not suitable to selectively identify the drug and to discriminate the parent drug from their metabolites (16) .
The present paper aims to evaluate the advantages and limitations of the use of IAs for forensic purposes on the basis of a National Proficiency Test (PT), for which we are the Reference Laboratory (RL). The study was conducted by comparing the liquid chromatography-tandem mass spectrometry (LC-MS-MS) method with the main IAs used in forensic toxicology ( Urine specimens were supplied by the Department of Security and Quality, Careggi Hospital of Florence, according to the scheme of the 'Regione Toscana' External Quality Assessment (EQA). These specimens consisted of liquid urine from drug abusers ( pool of several patients): thus, the samples are not statistically representative of the real population containing not only benzodiazepines (but also other drugs of abuse such as opiates, cocaine, cannabinoids, barbiturates and amphetamines). Urines were filtered and sodium azide was added as preservative. Twelve samples were analyzed to detect benzodiazepines and their metabolites. (Table I) , and they were performed according to the manufacturers' instructions, which indicate the method that each laboratory must apply for the instrument used, in order to provide the most reliable results and to compare with the others.
Enzymatic hydrolysis and liquid -liquid extraction
The supplied urine samples were already mixed by the Department of Security and Quality, Careggi Hospital of Florence and 1.0 mL was added with 1.0 mL of ammonium acetate buffer ( pH 4.5), 10 mL of b-glucuronidase and 20 mL of 500 ng/mL solution of IS, and then incubated for 18 h at 508C. After cooling at room temperature, 0.5 mL of NaOH 2 N was added. A liquid -liquid extraction (LLE) was performed by adding 5.0 mL of a 9 : 1 (v : v) dichloromethane and isopropanol mixture. After centrifugation at 4,000 rpm for 5 min, the lower organic layer was transferred into a tube, dried under a gentle stream of nitrogen at 408C and the residue dissolved in 100 mL of LC-MS CHROMASOLV w methanol. An aliquot of 3 mL was injected into the LC-MS-MS system.
LC-MS-MS
Analysis was conducted using an HPLC Agilent 1290 Infinity system (Agilent Technologies, Palo Alto, CA, USA) interfaced with an Agilent 6460 Triple Quad LC/MS (Agilent Technologies), coupled at an electrospray ion source (ESI). The column used was a Zorbax SB-C18 Rapid Resolution HT (2.1 Â 50 mm, 1.8 mm, Agilent Technologies), heated at 308C. The mobile phase initially consisted of 5 mM aqueous acid formic (A) and acetonitrile (B) 90 : 10. Gradient elution was carried out by increasing within 3 min, then running isocratically for 1 min; post-time was 1.5 min. The flow rate was 0.4 mL/min and the injection volume was 3 mL. The ESI configuration was: gas temperature 3258C; gas flow rate 10 L/min; nebulizer 20 psi; capillary 4,000 V. Multiple reaction monitoring (MRM) analysis was performed in the positive mode, with a dwell of 70 ms. Two transitions for each substance were chosen for identification; the most intense was used for quantification purposes (Table II) . Data acquisition and elaboration were performed by the Agilent MassHunter Workstation Software. Calibration levels were prepared by spiking blank urine with the benzodiazepine standards at 0.5, 1.0, 10.0, 50.0, 100.0, 500.0 and 1,000.0 ng/mL. Quantitative results were obtained by evaluating five replicates of each sample.
Results

Immunoassays
Each IA was evaluated by the calculation of different statistical parameters: true positive (TP), true negative (TN), FP, FN (according to the concentration of the benzodiazepines detected in the 
LC-MS-MS controls), SENS, SPEC, positive predictive value (PPV), negative predictive value (NPV) and accuracy (ACC). The equations used in these calculations are presented in Table III.  Table IV presents the qualitative results for each IA, using LC-MS-MS analysis as a reference point for determining positive and negative samples, considering the manufacturers' stated cutoff used for the IAs. From a quantitative point of view, the study was affected by the low number of responses provided by the participating laboratories, as shown in Table V . Concentration values correspond to the combined concentration of each substance, which is not a straightforward sum of each relevant molecule amount, instead it is necessary to take the individual cross-reactivity (and therefore the cutoff) for each analyte into account. Thus, concrete knowledge of the IA used appears crucial to avoid a misleading interpretation of the results, together with a complete case evaluation, especially in forensic toxicology. The concentration range was 193.5-517.5 ng/mL; it is possible to note that FPIA and KIMS tests yield lower values in the range, while CEDIA and EMITs values tend to be higher. In addition, KIMS and FPIA show a better percent coefficient of variation. Since the 12 urine specimens were prepared for a PT, they presented an imbalance between the positive and negative cases in favor of the positive ones; therefore, our evaluations concern this kind of population examined.
LC-MS-MS
In our laboratory, validated LC-MS-MS analyses of benzodiazepines and their metabolites are routinely used to confirm screening test results. The LLE employed in this study yielded recoveries above 90% for all benzodiazepines. Correlation coefficient values for the concentration range of 0.5-1,000.0 ng/mL were .0.99. Limits of detection (LODs) and quantification (LOQs) were measured by evaluating the signal/noise ratio (S/N) and were fixed at the concentration with a S/N ratio of .3 and .10, respectively. An LOQ value ranged from 0.01 ng/mL (a-hydroxyalprazolam) to 0.05 (oxazepam). In this study, LOQ was used as LOD. Urine is not the only biological specimen that we analyze. We also detect benzodiazepines and their metabolites in blood, hair and organs for different forensic aims (i.e., DFSA, DUID, and death).
Eleven different benzodiazepine structures were found in all urine specimens: diazepam, nordiazepam, oxazepam, temazepam, delorazepam, lorazepam, midazolam, a-hydroxymidazolam, alprazolam, a-hydroxyalprazolam and lormetazepam (Table VI) . This result was possible because, as mentioned above, the specimens were formed by mixing urines in different proportions from patients under addiction treatment. Thus, the interpretation of the results regarding the determination of parent drugs and their metabolites is complicated. In fact, nordiazepam, oxazepam and temazepam belong to the diazepam metabolic pathway, but they are drug substances in their own right, as well as lorazepam, which is a metabolite of delorazepam and lormetazepam (Figure 1) . Furthermore, the enzymatic hydrolysis procedures, used to de-conjugate benzodiazepine glucuronides during urine drug testing, are known to induce reductive transformation of oxazepam (into nordiazepam), temazepam (into diazepam) and lorazepam (into delorazepam) (17, 18) . Thus, with 199  47 22  1 100  32  82  81  96  200  EMIT-B  83  19 10  -100  34  83  81  100  200  EMIT-A  27  -6  -100  100  100  100  100  200  FPIA  34  6  1 13  72  14  65  85  7  200  KIMS  258  52 34  1 100  40  85  83  97  200  IMC  154 149 50  3  98  25  57  51  94  300 Not all participating laboratories provided a qualitative result. the exception of alprazolam, midazolam and lormetazepam, the other molecules may be both drugs and biotransformation products (metabolism and reductive activity of b-glucuronidase).
The total concentration range was 0-494.1 ng/mL and the most present benzodiazepine was lorazepam with an average of 134.2 ng/mL. Alprazolam and its metabolite a-hydroxyalprazolam were under LOQs in Samples 9 and 10. Low concentrations of diazepam (0.09-2.6 ng/mL), midazolam (0.2-1.2 ng/mL) and delorazepam (0.05-0.7 ng/mL) can be primarily explained by their extensive metabolism.
Discussion
The objective of the present study was to examine the performance of the main IAs in comparison with reference analysis by LC-MS-MS. Our results show that there is a very high SENS (72 -100%), but a low SPEC (14-42%, EMIT-A. excluded). This leads to a high FP rate, which in turn requires a high number of confirmation analyses. On the other hand, the possibility of FNs is a critical aspect that can generate errors of great severity: an unconfirmed FN case remains as negative data, leading to mistaken evaluations and potentially serious consequences, (Table VII) . Single cases excluded, KIMS and FPIA gave closer results to LC -MS-MS values than the other IAs. Since the IA responses depend on the affinity of the analyte to the antibody, it stands to reason that it is necessary to consider the cross-reactivity when evaluating semi-quantitative datum, bearing in mind that the result corresponds to a combined concentration. These considerations are very important in cases such as ours, where various structures are present in a single specimen, each with its own contribution to the combined concentration. It must be said that the molecules analyzed by the LC-MS-MS are different from those analyzed by the IAs, due to enzymatic hydrolysis effects. In fact, b-glucuronidase hydrolysis releases molecules unavailable for the antibodies already bound to glucuronic acid (oxazepam, temazepam, lorazepam, lormetazepam, a-hydroxyalprazolam and a-hydroxymidazolam), influencing in this way the results of the analysis. With the present study, we have succeeded in explaining the great differences that result from the different types of tests, and especially in comparison with the confirmation analyses.
Conclusions
Currently, IAs represent the main screening test for benzodiazepines and other molecules in many analytical environments, providing information about both positivity or negativity and about semi-quantitative determination. However, evaluation of the outcomes must consider the possibility of incorrect results, especially when classes of drugs with large structural variability are analyzed (i.e., benzodiazepines, amphetamine designer drugs). In the present study, CEDIA, EMITs and KIMS tests provided quite good levels of SENS, PPV and ACC, while FPIA presented the least reliable results for ACC, SENS and NPV. It should be noted that the SPEC values were very low for all the methods (except for EMIT-A.), with high FP rates. In light of all these aspects, the role of the confirmatory analysis is essential and it must be performed also for negative cases when an FN is probable. This study has also confirmed that semi-quantitative data from IAs are only indicative and they cannot replace instrumental techniques.
Furthermore, we wish to warn about the indiscriminate use of these tests without confirmation in forensic cases, i.e., cases involving the use of benzodiazepines in DUID, DFSA or other circumstances.
